

Figure S1. Pharmacokinetic Human Model Schematic of Remdesivir and Metabolites. Intravenous dosing of remdesivir is described by a two-compartment model with linear distribution, Q_{Rem}, between plasma, $V_{Rem,Plasma}$, and tissue, $V_{Rem,Tissue}$. Remdesivir is irreversibly metabolized to GS-441524 metabolite (Nuc) via a first-order rate constant, k_{met}. This metabolite is characterized by a two-compartment model with linear distribution, Q_{Nuc}, between plasma, $V_{Nuc,Plasma}$, and tissue, $V_{Nuc,Tissue}$. Nuc is eliminated linearly from plasma at rate CL_{Nuc}.